Bridgeway Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Bridgeway Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-35,000	Closed	-$534K	–	1499
2018 Q3	$534K	Sell	35,000 -25,000	-42%	-$364K	0.01%	1120
2018 Q2	$735K	Sell	60,000 -23,300	-28%	-$293K	0.01%	1005
2018 Q1	$796K	Sell	83,300 -66,600	-44%	-$718K	0.01%	924
2017 Q4	$1.35M	Sell	149,900 -18,400	-11%	-$135K	0.01%	719
2017 Q3	$968K	Buy	168,300 +75,000	+80%	+$273K	0.01%	854
2017 Q2	$296K	Hold	93,300	–	–	﹤0.01%	1210
2017 Q1	$317K	Hold	93,300	–	–	﹤0.01%	1199
2016 Q4	$269K	Hold	93,300	–	–	﹤0.01%	1251
2016 Q3	$549K	Buy	+93,300	New	+$327K	0.01%	1055
2016 Q2	–	Sell	-53,300	Closed	-$286K	–	1491
2016 Q1	$286K	Sell	53,300 -10,000	-16%	-$63.1K	﹤0.01%	1224
2015 Q4	$751K	Hold	63,300	–	–	0.01%	888
2015 Q3	$520K	Buy	63,300 +18,300	+41%	+$211K	0.01%	1006
2015 Q2	$628K	Hold	45,000	–	–	0.01%	960
2015 Q1	$1.08M	Hold	45,000	–	–	0.02%	759
2014 Q4	$741K	Buy	+45,000	New	+$519K	0.02%	891

Other funds holding DRNA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's DRNA Position: Q4 2018 in Review

Bridgeway Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2018, closing a stake of 35,000 shares — an estimated $534K sold.

Bridgeway Capital Management first reported a position in DRNA in Q4 2014 and held it in 15 quarters. The position peaked at $1.35M in Q4 2017. 103 funds tracked by Wall St. Rank hold DRNA as of Q4 2018.

Bridgeway Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Bridgeway Capital Management sold 35,000 Dicerna Pharmaceuticals, Inc. shares in Q4 2018, an estimated $534K.
Bridgeway Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2014 and held it in 15 quarters.
Bridgeway Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $1.35M in Q4 2017.
103 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2018.

Based on Bridgeway Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.